18 patents
Utility
Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose
20 Jul 23
Methods, pharmaceutical formulations and devices for the preventative treatment of incidental opioid overdose comprising the intramuscular or subcutaneous administration using an auto-injection device of a pharmaceutical formulation containing the opioid antagonist nalmefene as a prophylactic measure.
Roger Crystal, Phil Skolnick, Edward T. Maggio
Filed: 27 Feb 23
Utility
Methods and Compositions for Treating Cannabinoid Overdose with a Cannabinoid Receptor Antagonist
16 Mar 23
Disclosed herein are formulations and methods for reversing one or more symptoms of cannabinoid overdose, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the cannabinoid overdose symptoms.
Phil SKOLNICK
Filed: 14 Oct 22
Utility
Compositions and Methods for the Treatment of Opioid Overdose
23 Feb 23
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided.
Phil Skolnick, Mark Ellison, Roger Crystal
Filed: 4 Aug 22
Utility
Compositions and Methods for the Treatment of Opioid Overdose
8 Dec 22
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided.
Roger CRYSTAL, Edward T. MAGGIO
Filed: 4 Aug 22
Utility
Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
18 Oct 22
Disclosed herein are formulations and methods for reversing one or more symptoms of cannabinoid hyperemesis syndrome (CHS) or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the CHS or symptom(s).
Phil Skolnick
Filed: 17 Jun 20
Utility
Compositions and methods for the treatment of opioid overdose
4 Oct 22
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided.
Roger Crystal, Edward T. Maggio
Filed: 9 Nov 17
Utility
Nasal Drug Products and Methods of Their Use
10 Mar 22
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided.
Fintan KEEGAN, Robert Gerard BELL, Roger CRYSTAL, Michael Brenner WEISS
Filed: 17 Nov 21
Utility
Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose
30 Dec 21
Methods, pharmaceutical formulations and devices for the preventative treatment of incidental opioid overdose comprising the intramuscular or subcutaneous administration using an auto-injection device of a pharmaceutical formulation containing the opioid antagonist nalmefene as a prophylactic measure.
Roger Crystal, Phil Skolnick
Filed: 7 Nov 19
Utility
Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose
9 Sep 21
Methods, pharmaceutical formulations and devices for the preventative treatment of incidental opioid overdose comprising the intramuscular or subcutaneous administration using an auto-injection device of a pharmaceutical formulation containing the opioid antagonist nalmefene as a prophylactic measure.
Roger Crystal, Phil Skolnick
Filed: 13 May 21
Utility
Nasal Drug Products and Methods of Their Use
9 Sep 21
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided.
Roger CRYSTAL, Michael Brenner WEISS
Filed: 18 Dec 20
Utility
Formulations and Methods for the Prevention of Opioid Overdose
22 Jul 21
Formulations and methods for the preventative treatment of incidental opioid overdose comprising the intranasal (IN) administration of a pharmaceutical formulation containing the opioid antagonist nalmefene as a prophylactic measure.
Roger Crystal, Phil Skolnick, Edward T. Maggio
Filed: 15 May 19
Utility
Nasal Drug Products and Methods of Their Use
1 Apr 21
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided.
Fintan KEEGAN, Robert Gerard BELL, Roger CRYSTAL, Michael Brenner WEISS
Filed: 7 May 20
Utility
Compositions and Methods for Treating Cannabinoid Hyperemesis Syndrome with a Cannabinoid Receptor Antagonist
21 Jan 21
Disclosed herein are formulations and methods for reversing one or more symptoms of cannabinoid hyperemesis syndrome (CHS) or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the CHS or symptom(s).
Phil SKOLNICK
Filed: 17 Jun 20
Utility
Compositions and Methods for Treating Acute Cannabinoid Overdose with a Cannabinoid Receptor Antagonist
23 Dec 20
Provided are formulations and methods for treating, reversing, or reducing acute cannabinoid overdose, cannabinoid hyperemesis syndrome, or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the acute cannabinoid overdose, cannabinoid hyperemesis syndrome, or symptom(s) thereof.
Phil SKOLNICK
Filed: 16 Jun 20
Utility
Compositions, Devices, and Methods for the Treatment of Overdose and Reward-based Disorders
16 Dec 20
Drug products adapted for nasal delivery, comprising a device filled with a pharmaceutical composition comprising naltrexone are provided.
Edward T. Maggio, Roger Crystal, Mark Ellison, Phil Skolnick
Filed: 18 Dec 19
Utility
Compositions and Methods for Treating Acute Cannabinoid Overdose with a Cannabinoid Receptor Antagonist
10 Jun 20
Disclosed herein are formulations and methods for reversing cannabinoid overdose or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the cannabinoid overdose or symptom(s).
Phil SKOLNICK
Filed: 4 Dec 19
Utility
Compositions and Methods for the Treatment of Opioid Overdose
26 Feb 20
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided.
Roger Crystal, Edward T. Maggio
Filed: 8 Nov 17
Utility
Nasal Drug Products and Methods of Their Use
29 Jan 20
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided.
Fintan KEEGAN, Robert Gerard BELL, Roger CRYSTAL, Michael Brenner WEISS
Filed: 7 Oct 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first